Clinical Trial Update: Cell Therapy for High Risk T-Cell Malignancies Using CD7-Specific CAR Expressed On Autologous T Cells [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluates CD7-targeted CAR-T cells derived from autologous T cells for high-risk T-cell malignancies and is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• T-cell Acute Lymphoblastic Leukemia
• T-cell Acute Lymphoblastic Lymphoma
• T-cell Non-hodgkin Lymphoma

Drugs mentioned

• CD7-directed autologous CAR-T cell therapy

Snippet

Sponsor: Baylor College of Medicine | Conditions: T-cell Acute Lymphoblastic Lymphoma, T-non-Hodgkin Lymphoma | Phase 1 | Status: RECRUITING